• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Anal Cancer - Pipeline Review, Q4 2010 - Product Image

Anal Cancer - Pipeline Review, Q4 2010

  • ID: 1474106
  • December 2010
  • 37 pages
  • Global Markets Direct

Anal Cancer - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Anal Cancer Pipeline Review, Q4 2010”, provides an overview of the Anal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Anal Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anal Cancer . “Anal Cancer -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Anal Cancer   .
- A review of the Anal Cancer    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Anal Cancer
Anal Cancer Therapeutics under Development by Companies
Anal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Anal Cancer Therapeutics Development
PDS Biotechnology Corporation
Universities/Institutes Involved in Anal Cancer Therapeutics Development
Anal Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
5-Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + fluorouracil + mitomycin C + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rectogesic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos